Actelion Pharmaceuticals US, Inc. (ATLN.VX) Enters Phase III With Novel Orexin Receptor Antagonist Almorexant  
12/20/2007 10:10:43 AM

ALLSCHWIL, Switzerland, Dec. 20, 2007 (PRIME NEWSWIRE) -- Actelion Ltd (SWX:ATLN) announced today that the company has initiated the comprehensive Phase III program RESTORA (REstore physiological Sleep with The Orexin Receptor Antagonist Almorexant) with its first-in-class orexin receptor antagonist, almorexant.